Base-Case Costs and Ranges for Variables in the Model^*

Variable	Base-Case Cost, $	Range in Sensitivity Analyses, $	γ Distributions for Monte Carlo Simulations		References
			α	λ
Cost of administering clinical criteria†	50	40–60	11.11	0.22	90
Cost of tumor testing
BRAF testing	110	88–132	13.44	0.12	50
IHC	280	224–336	31.36	0.112	50
MSI	490	392–588	15.37	0.031	50
Cost of genetic testing and genetic counseling
Germline test for 1 gene	880	600–1200	19.36	0.022	50
Single-site mutation testing	460	200–475	9.40	0.020	50
Approaching relative to offer genetic testing	110	88–132	13.44	0.122	50
Initial genetic counseling visit	185	148–222	38.03	0.206	50
Follow-up genetic counseling visit	105	84–126	12.25	0.117	50
Cost of screening and complications
Colonoscopy	645	516–774	41.60	0.06	91
Colonoscopy complications
Bleeding	6218	4974–7462	17.18	0.003	90, 91
Perforation	10 304	8243–12 365	26.54	0.003	90, 91
Polypectomy and pathology	235	188–282	22.09	0.094	91
Endometrial biopsy	224	179–269	13.94	0.062	91
Transvaginal ultrasonography	110	88–132	13.44	0.012	91
Cost of risk-reducing surgeries
TAH-BSO	16 348	13 078–19 618	42.76	0.003	92
Subtotal colectomy	14 059	11 247–16 871	31.62	0.002	90, 91
Cost of colorectal cancer care in patients who do not have the Lynch syndrome
Without screening
Initial	43 471	34 777–52 165	18.90	0.0004	93
Year 1	3496	2797–4195	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 2	3184	2547–3821	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 3	3002	2402–3602	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 4	2904	2323–3485	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 5	2845	2276–3414	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
In year of death	52 440	41 952–62 928	27.50	0.0005	93
With screening
Initial	38 711	30 969–46 453	14.99	0.0004	93
Year 1	2978	2382–3574	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 2	2801	2241–3361	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 3	2701	2161–3241	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 4	2647	2118–3176	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 5	2615	2092–3138	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
In year of death	50 930	40 744–61 116	25.94	0.0005	93
Cost of colorectal cancer care in patients with the Lynch syndrome
Without screening
Initial	38 568	30 854–46 282	14.87	0.0004	93
Year 1	3060	2448–3672	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 2	2839	2271–3407	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 3	2715	2172–3258	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 4	2649	2119–3179	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 5	2610	2088–3132	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
In year of death	51 978	41 582–62 374	27.02	0.0005	93
With screening
Initial	33 711	26 969–40 453	11.36	0.0003	93
Year 1	2457	1966–2948	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 2	2447	1958–2936	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 3	2439	1951–2927	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 4	2433	1946–2920	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
Year 5	2428	1942–2914	Not varied in sensitivity analyses	Not varied in sensitivity analyses	93
In year of death	49 210	39 368–59 052	24.22	0.0005	93
Cost of cancer care
Endometrial cancer	31 027	24 822–37 232	15.04	0.0005	92
Ovarian cancer	32 379	25 903–38 855	10.48	0.0003	94

IHC = immunohistochemistry; MSI = microsatellite instability; TAH-BSO = total abdominal hysterectomy and bilateral salpingo-oophorectomy.

^*All costs are in 2010 U.S. dollars.

^†Amsterdam II criteria, revised Bethesda Guidelines, or prediction models (MMRpredict, MMRpro, and PREMM[1,2,6]).